clinical trial · NCT05461170
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Hepatitis D, ChronicVIR-2218VIR-3434NRTI
brief summary
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
started
Sep 17, 2022
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Oct 14, 2025
detailed description
Participants may be enrolled into Cohort 1 (1a and 1b) or Cohort 2 (2a, 2b1 or 2b2, 2c), 3, 4, and 5. All participants still receiving VIR-2218 or VIR-3434 monotherapy at the time of implementation of Protocol Amendment 4 will switch to combination therapy at Week 132 (Cohort 2a, 2b1/2b2) or Week 112 (Cohort 3).
official title
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol